Ming He, M.D., Ph.D., an assistant professor at the University of Alabama at Birmingham ’s Marnix E. Heersink School of ...
3don MSN
Sangamo targets Q1 2026 BLA submission for Fabry gene therapy as FDA affirms accelerated pathway
Discover Sangamo Therapeutics’ Q3 2025 highlights: clinical progress in Fabry disease, FDA support for ST-920, extended cash runway, and partnership updates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback